Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | CTSB | P07858 | 5/20 | 0.35 |
| ▸ | CTSL | P07711 | 5/20 | 0.35 |
| ▸ | CTSS | P25774 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7848739 | 0.90 | HTT (0.43) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7855773 | 0.86 | HTT (0.44) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7856659 | 0.85 | HTT (0.44) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7857519 | 0.85 | HTT (0.45) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7856575 | 0.84 | EPHX2 (0.39) | ALDH1A1KDM4EHPGDCTSKCTSB | |
| SCHEMBL7855800 | 0.84 | CTSK (0.37) | CTSKCTSBCTSLCTSSCYP3A4 | |
| SCHEMBL7855709 | 0.81 | HTT (0.47) | HTTSMN1; SMN2ALDH1A1LMNAKDM4E | |
| SCHEMBL7856622 | 0.79 | NPC1 (0.47) | SMN1; SMN2ALDH1A1KMT2AMEN1CTSK | |
| SCHEMBL7857584 | 0.79 | CTSK (0.49) | SMN1; SMN2LMNAHPGDUSP2TSHR | |
| SCHEMBL7857685 | 0.79 | BRD4 (0.38) | SMN1; SMN2ALDH1A1LMNAKDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009132453-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | NEUROMED PHARMACEUTICALS LTD. (CA) | 2009-11-05 | — | — | WO | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090270394-A1 | CYCLYLAMINE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1G, CACNA1H, CACNA1I | HTT 1084/4885SMN1; SMN2 2346/4885ALDH1A1 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.